Instituto de Investigación Sanitaria Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2024

  1. Sequential RAS mutations evaluation in cell-free DNA of patients with tissue RAS wild-type metastatic colorectal cancer: the PERSEIDA (Cohort 2) study

    Clinical and Translational Oncology

2023

  1. An international comparative analysis and roadmap to sustainable biosimilar markets

    Frontiers in Pharmacology, Vol. 14

  2. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  3. Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement

    Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3378-3394

2021

  1. Biomarkers associated with regorafenib first-line treatment benefits in metastatic colorectal cancer patients: Reframe molecular study

    Cancers, Vol. 13, Núm. 7

  2. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  3. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

2020

  1. Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status

    Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 2026-2031

2014

  1. Validaciónde polimorfismos genéticos asociados a toxicidad al tratamiento quimioteŕapico en pacientes de cancer colorrectal

    Farmacia Hospitalaria, Vol. 38, Núm. 4, pp. 283-290

2013

  1. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer

    Cancer Chemotherapy and Pharmacology, Vol. 71, Núm. 6, pp. 1463-1472

  2. Erratum: Differential toxicity biomarkers for irinotecan and oxaliplatin containing chemotherapy in colorectal cancer (Cancer Chemotherapy and Pharmacology (2013) 71 (1463-1472) DOI: 10.1007/s00280-013-2145-6)

    Cancer Chemotherapy and Pharmacology